Sectors
KNSA
Kiniksa Pharmaceuticals International, plc
62.23
1 x 62.20
3 x 62.28
bid
ask
-
1.32
2.08%
03:16 PM
timesize
| Ytd | 50.85% | |
| 1y | 125.13% |
61.60
day range
63.82
26.27
52 week range
67.53
| Open | 63.23 | Prev Close | 63.55 | Low | 61.60 | High | 63.82 | Mkt Cap | 4.78B |
| Vol | 185.10K | Avg Vol | 788.93K | EPS | 0.90 | P/E | 70.61 | Forward P/E | 58.14 |
| Beta | 0.07 | Short Ratio | 4.30 | Inst. Own | 102.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 56.66 | 200-d Avg | 46.67 | 1yr Est | 68.13 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-07-28 | 2026-06 | 0.3 | N/A | N/A | N/A |
| 2026-04-28 | 2026-03 | 0.18 | 0.27 | 0.09 | 50.00% |
| 2026-02-24 | 2025-12 | 0.29 | 0.17 | -0.12 | -41.38% |
| 2025-10-28 | 2025-09 | 0.33 | 0.23 | -0.1 | -30.30% |
| 2025-07-29 | 2025-06 | 0.18 | 0.23 | 0.05 | 27.78% |
| 2025-04-29 | 2025-03 | 0.02 | 0.11 | 0.09 | 450.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-29 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-29 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-04-29 | Citigroup | Upgrade | Buy | Buy |
| 2026-04-29 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-29 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-04-28 | Jefferies | Upgrade | Buy | Buy |
Profile
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-28 | BAKER BROS ADVISORS L.P. | Unknown | 0.00 | Stock Award(Grant) |
| 2025-06-02 | BAKER BROTHERS LIFE SCIENCES, L.P. | Director | 0.00 | Stock Award(Grant) |
| 2026-05-28 | LEVY RICHARD S | Director | 21.96K | Conversion of Exercise of derivative security |
| 2026-05-28 | MALLEY THOMAS ROBERT | Director | 87.31K | Conversion of Exercise of derivative security |
| 2026-04-08 | MEGNA MICHAEL R | Officer | 27.42K | Sale |
| 2026-04-30 | PAOLINI JOHN F | Officer | 65.62K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR Inc | 6.82M | 0.00 | 8.87% |
| 2026-03-30 | Rubric Capital Management LP | 3.75M | 0.00 | 4.87% |
| 2025-12-30 | Vanguard Group Inc | 3.11M | 0.00 | 4.05% |
| 2026-03-30 | Baker Bros Advisors LP | 2.83M | 0.00 | 3.67% |
| 2026-03-30 | TANG CAPITAL MANAGEMENT LLC | 2.26M | 0.00 | 2.94% |
| 2026-03-30 | Vanguard Portfolio Management, LLC | 1.77M | 0.00 | 2.30% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 1.32M | 0.00 | 1.71% |
| 2026-06-29 | iShares Russell 2000 ETF | 1.10M | 0.00 | 1.43% |
| 2026-06-29 | Vanguard Small Cap Index | 955.92K | 0.00 | 1.24% |
| 2026-05-30 | Fidelity Select Health Care | 844.91K | 0.00 | 1.10% |
| 2026-05-30 | Fidelity Select Biotechnology | 637.60K | 0.00 | 0.83% |
| 2026-05-30 | Strategic Advisers Fidelity US TtlStk | 601.05K | 0.00 | 0.78% |